Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Rohit BishnoiYoung-Rock HongChintan ShahAzka AliWilliam P SkeltonJinhai Stephen HuoNam H DangLong H DangPublished in: Cancer medicine (2019)
DPP4 inhibition in CRC and lung cancer is associated with improved OS, which possibly may be due to the effect of DPP4 inhibition on immunoregulation of cancer.